大规模使用中3岁及以上人群接种灭活SARS-CoV-2疫苗(CoronaVac®)基础免疫的安全性:中国多中心开放标签研究
在中国11个省份开展多中心开放标签研究,纳入3岁及以上无COVID-19疫苗接种史或仅接种一剂CoronaVac®者,包括有基础疾病的成人和老年人,接种一或两剂(间隔28天),收集第二剂后6个月内不良事件。共纳入162,691人,89.50%完成基础免疫,总不良反应发生率为2.70%,未报告疫苗相关严重不良事件,未发现特别关注不良事件。
要点
- 第二剂后6个月内总不良反应发生率为2.70%,多为轻度(1级)。
- 儿童青少年、成人、老年人不良反应发生率分别为2.03%、3.46%、1.90%。
- 有基础疾病者与无基础疾病者不良反应发生率分别为2.81%和2.99%,无统计学显著差异(P=0.089)。
核心结论
- CoronaVac®在大规模使用中是安全的,对儿童青少年和有基础疾病者耐受良好。
- 需进一步研究探讨不良反应发生率与年龄或不同基础疾病的关系。
研究设计与样本
- 多中心开放标签研究,在中国11个省份开展。
- 纳入3岁及以上无COVID-19疫苗接种史或仅接种一剂CoronaVac®者,包括有或无基础疾病的成人和老年人。
- 符合条件者接种一或两剂CoronaVac®,间隔28天。
- 由参与者或监护人通过研究设计的数据收集系统记录人口学信息、疫苗接种和不良事件发生情况。
- 收集第二剂接种后6个月内发生的所有不良事件。
主要发现
- 共纳入162,691名参与者,89.50%完成基础免疫。
- 成人和老年人中有基础疾病者占25.85%,前五位疾病为高血压、糖尿病、慢性胃炎、冠心病和肾结石。
- 第二剂接种后6个月内总不良反应发生率为2.70%,儿童青少年、成人、老年人分别为2.03%、3.46%、1.90%。
- 大多数不良反应为轻度(1级),最常见为注射部位疼痛(1.64%)、乏力(0.46%)、硬结/肿胀(0.31%)和头痛(0.24%)。
- 未报告疫苗相关严重不良事件,未发现特别关注不良事件(AESIs)。
局限性
- 需进一步研究探讨不良反应发生率与年龄或不同基础疾病的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety of primary immunization using CoronaVac® among population aged 3 years and above in a large-scale use. METHOD: A multi-center open-label study was carried out in 11 provinces of China. Individuals aged 3 years and older who had no history of COVID-19 vaccination or had received only one dose of CoronaVac® were enrolled in this study. Adults and elderly with or without underlying medical conditions(UMCs) were also recruited. Eligible participants received one or two doses of CoronaVac® with an interval of 28 days. Demographic information, vaccination and the occurrence of adverse events were recorded by participants or guardians using data collection system designed for this study. All adverse events occurred within 6 months after the second dose of vaccination were collected. The incidence of adverse events that cannot be ruled out as being caused by the vaccine were calculated to assess the safety of CoronaVac®. This study is registered with ClinicalTrials. Gov (NCT04911790 and NCT04992208). RESULTS: A total of 162,691 participants have been included in this study and 89.50 % had finished primary immunization. Among adults and elderly, people with UMCs accounted for 25.85 %, with the top five disease being hypertension, diabetes, chronic gastritis, coronary heart disease(CHD) and kidney stone. The overall incidence of adverse reactions (ARs) within 6 months after the second vaccination was 2.70 %, with incidence for children and adolescents, adults, and elderly being 2.03 %, 3.46 %, and 1.90 %, respectively. Most ARs were mild (grade 1). Pain at the injection sites, fatigue, induration/swelling, and headache were the most common symptoms, occurring in 1.64 %, 0.46 %, 0.31 % and 0.24 %, respectively. No serious adverse events related to vaccines were reported. No adverse events of special interest (AESIs) were identified. For children and adolescents, children aged 3-5 years had the highest incidence of ARs of 3.29 %. The incidence of ARs among those aged 18 years and older with and without UMCs were 2.81 % and 2.99 %, respectively, with no statistical significance between two groups(P = 0.089). And people with coronary heart disease had higher AR incidence compared to those with other UMCs, but the most common symptoms was pain at the injection site. CONCLUSION: CoronaVac® is safe in a large-scale use and shows well-tolerance for children and adolescents and people with underlying medical conditions. Further studies need to be conducted to explore the relation of ARs incidence to age or different kinds of UMCs.
引用
- Yang H, Li Z, Zhang R, et al. Safety of primary immunization using inactivated SARS-CoV-2 vaccine (CoronaVac®) among population aged 3 years and older in a large-scale use: A multi-center open-label study in China. Vaccine. 2023. PMID: 36658045. doi:10.1016/j.vaccine.2023.01.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。